The move comes as GSK faces pressure to replenish its pipeline, with some of its top-selling drugs nearing the end of their exclusivity periods.

GSK plc GSK announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston Pharmaceuticals to acquire the latter’s lead pipeline drug, efimosfermin alfa. Efimosfermin is an investigational long-acting variant of FGF21 protein designed to treat and prevent the progression of steatotic liver disease (SLD),

GSK will buy efimosfermin, a liver disease drug in late-stage trials, for up to $2 billion from U.S. biotechnology firm Boston Pharmaceuticals, the British drugmaker said on Wednesday.